<DOC>
	<DOCNO>NCT00020761</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine irinotecan paclitaxel treat patient metastatic recurrent cancer esophagus stomach .</brief_summary>
	<brief_title>Irinotecan Paclitaxel Treating Patients With Metastatic Recurrent Cancer Esophagus Stomach</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor activity irinotecan paclitaxel patient metastatic recurrent adenocarcinoma esophagus stomach . - Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients stratify accord diagnosis ( adenocarcinoma esophagus , gastroesophageal junction , gastric cardia v adenocarcinoma rest stomach ) . Patients receive irinotecan IV 90 minute follow paclitaxel IV 3 hour day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Patients follow 30 day every 3 month thereafter . PROJECTED ACCRUAL : A total 26-54 patient ( 13-27 per stratum ) accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion Criteria Patients histologic proof adenocarcinoma esophagus ( include GE junction ) adenocarcinoma stomach eligible . Location tumor assignment study determine prior endoscopy barium contrast study . Patients must either metastatic recurrent cancer . Patients must bidimensionally measurable disease , define Section 8.4.1.1 , page 16 . Mediastinal hilar lymph node assess CT MRI scan must least 2 cm large dimension consider measurable . Prior limited radiation therapy permit . Prior radiotherapy must include major bone marrow contain area ( pelvis , lumbar spine ) , contain single evaluable lesion radiation field . A recovery period least 4 week completion radiotherapy require prior study treatment . Patients must anticipate life expectancy least 12 week . Patients must performance status 0 1 ECOG performance scale . Patients must &gt; 18 year old . Patients must give write informed consent prior enrollment . Patients adequate organ function define follow : Absolute granulocytes &gt; 1,500/mm3 platelet &gt; 100,000/mm3 ; serum bilirubin &lt; 1.5 mg/dL SGOT &lt; 3X upper limit institutional norm ; serum creatinine &lt; 1.5 mg/dL . Patients must recover recent surgery . One week must elapse time minor surgery 3 week major surgery . Exclusion Criteria Patients receive one prior chemotherapy regimen immunotherapy metastatic disease . Prior 5FU alone adjuvant therapy radiosensitizer count . Patients must interval 4 week prior chemotherapy immunotherapy full recovery . Patients receive concurrent chemotherapy , immunotherapy , radiotherapy . Patients potentially curable chemotherapy , radiotherapy , surgery , combination . Patients know brain metastasis . Patients history seizure receive phenytoin , phenobarbital , antiepileptic prophylaxis . Pregnant lactating woman . All woman childbearing potential must negative pregnancy test prior entry study . All patient procreative potential must advise importance avoid pregnancy use appropriate method contraception participate investigational trial . Patients serious intercurrent infection , concurrent disease , investigator 's judgment , would make patient inappropriate entry study . Patients psychiatric disorder render incapable complying requirement protocol . Patients osseous metastasis site disease . Patients concurrent active malignancy nonmelanoma skin cancer carcinomainsitu cervix . Patients previous malignancy without evidence disease &gt; 5 year allow enter trial . Patients know Gilbert 's syndrome . Patients significant clinical neuropathy great grade 2 . Patients unstable angina , history myocardial infarction within previous 6 month , current clinical evidence congestive heart failure . Patients take medication congestive heart failure show clinical sign symptom eligible . Patients previously receive taxane campthothecin Patients receive investigational therapy within previous 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>